Compare Cytokinetics Inc (CYTK) vs Duke Energy Corp (DUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Duke Energy Corp — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Duke Energy Corp trades at $116.8 (market cap $91.10B). The key difference: Duke Energy Corp is far larger — about 10.6× Cytokinetics Inc's market cap, and Duke Energy Corp pays a 3.71% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Duke Energy Corp for 74 Days on average.
| CYTK | DUK | |
|---|---|---|
Market Cap | $8.62B | $91.10B |
Volume | 2,594,626 | 4,199,050 |
Sector | Health | Utilities |
52-Week High | $87.26 | $133.46 |
52-Week Low | $54.76 | $113.23 |
Typical Hold Time | 19 Days | 74 Days |
Enterprise Value | $8.72B | $183.61B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Duke Energy (DUK) trades at $115.5, down 0.14% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $28.8B in 2022 to $32.2B in 2025, and a net income margin of 15.78%. Recent news highlights dividend stability and data center-driven growth opportunities, though rising Treasury yields pressure utility stocks.
DUK offers a balanced outlook with steady dividends and growth from data center demand, but faces risks from high debt levels and interest rate sensitivity. Analyst consensus is mixed with a $135.33 price target, suggesting 17% upside, supported by a 43.75% buy rating. Investors should weigh solid profitability against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
